LakeShore Biopharma Announces Fiscal Year 2025 Financial Results
LakeShore Biopharma (NASDAQ:LSB) reported its FY2025 financial results, showing mixed performance with improvements in profitability despite missing guidance targets. Total revenue increased 7.2% to RMB615.0 million, while gross profit rose 11.3% to RMB507.2 million with improved margins of 82.5%.
The company significantly narrowed its net loss to RMB100.0 million from RMB433.5 million in FY2024, while operating expenses decreased by 34.2%. Their flagship product, YSJATM rabies vaccine, has been administered in approximately 110 million doses and distributed to 1,911 county-level CDCs in China. The company is advancing a Phase III trial for a simplified four-dose regimen, targeting market approval by Q4 2026.
For FY2026, LSB projects revenue between RMB550-650 million, while facing challenges including intensified competition, pricing pressures, and ongoing litigation with their former Chairman affecting credit access.
LakeShore Biopharma (NASDAQ:LSB) ha comunicato i risultati finanziari per l'anno fiscale 2025, mostrando una performance mista con miglioramenti nella redditivit脿 nonostante non abbia raggiunto gli obiettivi di guidance. Il fatturato totale 猫 aumentato del 7,2% raggiungendo 615,0 milioni di RMB, mentre il profitto lordo 猫 cresciuto dell'11,3% arrivando a 507,2 milioni di RMB con margini migliorati all'82,5%.
L'azienda ha ridotto significativamente la perdita netta a 100,0 milioni di RMB rispetto ai 433,5 milioni di RMB dell'anno fiscale 2024, mentre le spese operative sono diminuite del 34,2%. Il prodotto di punta, il vaccino antirabbico YSJA鈩�, 猫 stato somministrato in circa 110 milioni di dosi e distribuito a 1.911 CDC a livello di contea in Cina. L'azienda sta portando avanti una sperimentazione di Fase III per un regime semplificato di quattro dosi, con l'obiettivo di ottenere l'approvazione di mercato entro il quarto trimestre del 2026.
Per l'anno fiscale 2026, LSB prevede un fatturato compreso tra 550 e 650 milioni di RMB, affrontando per貌 sfide quali una concorrenza pi霉 intensa, pressioni sui prezzi e contenziosi in corso con l'ex Presidente, che influenzano l'accesso al credito.
LakeShore Biopharma (NASDAQ:LSB) report贸 sus resultados financieros del a帽o fiscal 2025, mostrando un desempe帽o mixto con mejoras en la rentabilidad a pesar de no alcanzar las metas de gu铆a. Los ingresos totales aumentaron un 7,2% hasta 615,0 millones de RMB, mientras que la ganancia bruta subi贸 un 11,3% a 507,2 millones de RMB con m谩rgenes mejorados del 82,5%.
La compa帽铆a redujo significativamente su p茅rdida neta a 100,0 millones de RMB desde 433,5 millones de RMB en el a帽o fiscal 2024, mientras que los gastos operativos disminuyeron un 34,2%. Su producto estrella, la vacuna contra la rabia YSJA鈩�, ha sido administrada en aproximadamente 110 millones de dosis y distribuida a 1.911 CDC a nivel de condado en China. La empresa avanza en un ensayo de Fase III para un r茅gimen simplificado de cuatro dosis, con la meta de obtener la aprobaci贸n del mercado para el cuarto trimestre de 2026.
Para el a帽o fiscal 2026, LSB proyecta ingresos entre 550 y 650 millones de RMB, enfrentando desaf铆os como una competencia intensificada, presiones en los precios y litigios en curso con su ex presidente que afectan el acceso al cr茅dito.
LakeShore Biopharma (NASDAQ:LSB)電� 2025 須岅硠鞐半弰 鞛 鞁れ爜鞚� 氚滍憸頄堨溂氅�, 臧�鞚措崢鞀� 氇╉憸鞐愲姅 氙胳箻歆� 氇豁枅歆�毵� 靾橃澋靹膘潃 臧滌劆霅� 順检灛霅� 靹标臣毳� 氤挫榾鞀惦媹雼�. 齑� 毵れ稖鞚� 7.2% 歃濌皜頃� 6鞏� 1,500毵� 鞙勳晥鞚� 旮半頄堦碃, 齑濎澊鞚奠潃 11.3% 歃濌皜頃� 5鞏� 720毵� 鞙勳晥鞙茧 毵堨鞚� 82.5%搿� 頄レ儊霅橃棃鞀惦媹雼�.
須岇偓電� 2024 須岅硠鞐半弰鞚� 4鞏� 3,350毵� 鞙勳晥 靾滌啇鞁れ棎靹� 1鞏� 鞙勳晥鞙茧 靾滌啇鞁れ潉 韥矊 欷勳榾鞙茧┌, 鞓侅梾牍勳毄鞚� 34.2% 臧愳唽頄堨姷雼堧嫟. 欤茧牓 鞝滍拡鞚� YSJA鈩� 甏戧铂氤� 氚膘嫚鞚� 鞎� 1鞏� 1觳滊 霃勳臧� 韴棳霅橃棃瓿� 欷戧淡 雮� 1,911臧� 順� CDC鞐� 氚绊彫霅橃棃鞀惦媹雼�. 須岇偓電� 臧勳唽頇旊悳 4須� 鞝戩 鞖旊矔鞐� 雽�頃� 3靸� 鞛勳儊鞚� 歆勴枆 欷戩澊氅�, 2026雲� 4攵勱赴 鞁滌灔 項堦皜毳� 氇╉憸搿� 頃橁碃 鞛堨姷雼堧嫟.
2026 須岅硠鞐半弰鞐愲姅 LSB臧� 5鞏� 5,000毵寏6鞏� 5,000毵� 鞙勳晥鞚� 毵れ稖鞚� 鞓堨儊頃橁碃 鞛堨溂雮�, 瓴届焷 鞁檾, 臧�瓴� 鞎曤皶, 鞝� 須岇灔瓿检潣 歆�靻� 欷戩澑 靻岇啞鞙茧 鞚疙暅 鞁犾毄 鞝戧芳靹� 氍胳牅 霌� 鞐煬 霃勳爠鞐� 歆侂┐頃� 鞛堨姷雼堧嫟.
LakeShore Biopharma (NASDAQ:LSB) a publi茅 ses r茅sultats financiers pour l'exercice 2025, affichant une performance mitig茅e avec des am茅liorations de la rentabilit茅 malgr茅 un non-respect des objectifs pr茅vus. Le chiffre d'affaires total a augment茅 de 7,2 % pour atteindre 615,0 millions de RMB, tandis que le b茅n茅fice brut a progress茅 de 11,3 % 脿 507,2 millions de RMB avec une marge am茅lior茅e de 82,5 %.
L'entreprise a consid茅rablement r茅duit sa perte nette 脿 100,0 millions de RMB contre 433,5 millions de RMB en 2024, tandis que les charges d'exploitation ont diminu茅 de 34,2 %. Leur produit phare, le vaccin antirabique YSJA鈩�, a 茅t茅 administr茅 脿 environ 110 millions de doses et distribu茅 脿 1 911 CDC au niveau des comt茅s en Chine. La soci茅t茅 fait progresser un essai de phase III pour un sch茅ma simplifi茅 en quatre doses, visant une approbation du march茅 d'ici le quatri猫me trimestre 2026.
Pour l'exercice 2026, LSB pr茅voit un chiffre d'affaires compris entre 550 et 650 millions de RMB, tout en faisant face 脿 des d茅fis tels qu'une concurrence accrue, des pressions sur les prix et des litiges en cours avec leur ancien pr茅sident, affectant l'acc猫s au cr茅dit.
LakeShore Biopharma (NASDAQ:LSB) ver枚ffentlichte seine Finanzergebnisse f眉r das Gesch盲ftsjahr 2025 und zeigte eine gemischte Leistung mit Verbesserungen in der Rentabilit盲t, obwohl die Prognoseziele verfehlt wurden. Der Gesamtumsatz stieg um 7,2 % auf 615,0 Millionen RMB, w盲hrend der Bruttogewinn um 11,3 % auf 507,2 Millionen RMB mit verbesserten Margen von 82,5 % zunahm.
Das Unternehmen verringerte seinen Nettoverlust deutlich auf 100,0 Millionen RMB von 433,5 Millionen RMB im Gesch盲ftsjahr 2024, w盲hrend die Betriebskosten um 34,2 % sanken. Ihr Flaggschiffprodukt, der YSJA鈩� Tollwutimpfstoff, wurde in etwa 110 Millionen Dosen verabreicht und an 1.911 CDC auf Kreisebene in China verteilt. Das Unternehmen f眉hrt eine Phase-III-Studie f眉r ein vereinfachtes Vier-Dosen-Regime durch und strebt eine Marktzulassung bis zum vierten Quartal 2026 an.
F眉r das Gesch盲ftsjahr 2026 prognostiziert LSB einen Umsatz zwischen 550 und 650 Millionen RMB, sieht sich jedoch Herausforderungen wie verst盲rktem Wettbewerb, Preisdruck und laufenden Rechtsstreitigkeiten mit dem ehemaligen Vorsitzenden gegen眉ber, welche den Zugang zu Krediten beeintr盲chtigen.
- Net loss significantly narrowed by 77% year-over-year to RMB100.0 million
- Gross margin improved to 82.5% from 79.5% in previous year
- Total operating expenses decreased 34.2% year-over-year
- YSJATM rabies vaccine achieved 67.7% coverage across Chinese CDCs
- R&D expenses decreased significantly due to completed trials and cost optimization
- Failed to meet revenue guidance of RMB665-700 million
- Missed adjusted EBITDA guidance range of RMB76-89 million
- Cash and equivalents decreased to RMB107.5M from RMB246.6M year-over-year
- Short-term loans increased to RMB390.4M from RMB318.5M
- Ongoing litigation with former Chairman limiting access to new credit lines
Insights
LakeShore Biopharma shows significant financial improvement with narrowing losses despite missing guidance targets.
LakeShore Biopharma's FY2025 results present a company making substantial progress toward profitability despite falling short of guidance targets. The 7.2% revenue growth to
The improved gross margin of
However, investors should note the company missed both revenue and adjusted EBITDA guidance. The company cited increased competition in the rabies vaccine market, pricing pressures, distribution channel limitations, and ongoing cash constraints due to litigation with its former Chairman as contributing factors.
The balance sheet shows declining cash reserves of
While the company's YSJATM rabies vaccine maintains strong market presence with distribution to
- Total revenue reached
RMB615.0 million , representing7.2% year-over-year growth - Gross profit rose to
RMB507.2 million , up11.3% year-over-year - Gross margin improved to
82.5% from79.5% in Fiscal Year 2024 - Total operating expenses decreased
34.2% year-over-year toRMB593.5 million - EBITDA[1] and Adjusted EBITDA[2] were
RMB(48.5 million) andRMB0.6 million , respectively, compared toRMB(368.7 million) andRMB(236.4 million) in Fiscal Year 2024 - Net loss narrowed to
RMB100.0 million , with an adjusted net loss[3] ofRMB40.0 million , compared toRMB433.5 million andRMB266.3 million , respectively, in Fiscal Year 2024
"We are pleased to announce LakeShore Biopharma's FY2025 financial results with a
Mr. Xu Wang further commented: "Looking forward, we will strategically allocate our resources to maximize the commercial value of our flagship product, YSJATM rabies vaccine. Specifically, we will strive to maintain and grow our market share through the following measures: 1) expanding our coverage regions; 2) retaining and attracting high-performing CSOs; 3) driving end-market demand through collaboration with hospitals and clinics; 4) continuing to train and recruit new commercial talents; and 5) advancing the Phase III trial of the simplified four-dose regimen for the YSJATM rabies vaccine at full speed, with the goal of securing the market approval by the fourth quarter of 2026. Additionally, we will continue to enhance operational efficiency, reinforce cost control measures, and strengthen internal corporate governance."
Business Updates
YSJATM Rabies Vaccine
LakeShore Biopharma's YSJATM rabies vaccine is
Clinical Pipeline
Progress of Phase III Clinical Trial on simplified four-dose regimen for YSJATM rabies vaccine
In October 2024, the NMPA approved LakeShore Biopharma to initiate a Phase III clinical trial evaluating a simplified four-dose regimen for YSJATM, including the
LakeShore Biopharma commenced this clinical trial in December 2024 and successfully completed the 90-day subject follow-up in July 2025. The Company expects to finish the interim analysis in the fourth quarter of 2025 and obtain the market approval in the fourth quarter of 2026.
The study aims to strengthen the competitiveness of the YSJATM rabies vaccine in the rapidly growing rabies vaccine market, demonstrate its clinical superiority, and garner broader recognition and support from hospitals, academic institutions, and industry stakeholders in
Fiscal Year 2025听Financial Results
Total Revenue
Total revenue rose by
Gross Profit
Gross profit rose by
Selling and Marketing Expenses
Selling and marketing ("S&M") expenses decreased by
General and Administrative Expenses
General and administrative expenses decreased by
Research and Development Expenses
Research and development ("R&D")expenses in FY 2025 were
Impairment Loss on Inventory, Property, Plant and Equipment, and Other Assets
Impairment loss on inventory, property, plant and equipment, and other assets decreased by
EBITDA and Adjusted EBITDA
EBITDA[1] and Adjusted EBITDA[2] were
Loss from Operations
Operating loss was
Net Loss and Adjusted Net Loss
Net loss was
Balance Sheet
As of March 31, 2025, the Company had cash and cash equivalents of
Business Outlook
The Company anticipates total revenue in FY2026 to be between approximately
The above outlook is based on the information available as of the date of this press release and reflects the Company's current and preliminary expectations regarding its business situation and market conditions. The outlook is subject to changes, especially given uncertainties and situations related to market competitive dynamics, regulatory policies and other factors beyond its control.
[1]听EBITDA is a non-GAAP financial measure, which is defined as net income (loss) before income tax benefit (expense), financial expenses and depreciation and amortization. See "Use of Non-GAAP Financial Measures" below |
[2]听Adjusted EBITDA is a non-GAAP financial measure, which is defined as net income(loss) before income tax benefit (expense), financial expenses, and depreciation and amortization ("EBITDA") adjusted to exclude share-based compensation expenses, impairment loss on inventory, property, plant and equipment and other assets, late fees related to social security insurance, other income (expense), fair value changes of warrant liability, and government grants. See "Use of Non-GAAP Financial Measures" below |
[3]听Adjusted net income (loss) is a non-GAAP financial measure, which is defined as net income (loss) excluding share-based compensation expenses, impairment loss on inventory, property, plant and equipment and other assets, and loss on disposal of property, plant and equipment. See "Use of Non-GAAP Financial Measures" below. |
About LakeShore Biopharma听
LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA庐听immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Hepatitis B, Influenza, and other virus infections. The Company operates in
Use of Non-GAAP Financial Measures
In evaluating the business, the Company considers and uses certain non-GAAP measures, including Adjusted EBITDA and adjusted net income (loss), as supplemental measures to review and assess its operating performance. The presentation of the non-GAAP financial measure is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with
The non-GAAP financial measures are not defined under
The Company compensates for these limitations by reconciling the non-GAAP financial measure to the nearest
Reconciliations of LakeShore Biopharma's non-GAAP financial measures to the most comparable
Exchange Rate Information
This announcement contains translations of certain RMB amounts into
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the expected growth and business outlook of LakeShore Biopharma, the development progress of all product candidates, the progress and results of all clinical trials, LakeShore Biopharma's ability to source and retain talent, and the cash position of LakeShore Biopharma. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "potential," "forecast," "intend," "will," "expect," "anticipate," "believe," "goal," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether identified in this press release, and on the current expectations of LakeShore Biopharma's management and are not predictions of actual performance.
LakeShore Biopharma cannot assure you the forward-looking statements in this press release will be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including those included under the heading "Risk Factors" in the company's Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, and other risks described in documents subsequently filed by the company from time to time with the SEC. There may be additional risks that LakeShore Biopharma does not presently know or that LakeShore Biopharma currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of LakeShore Biopharma as of the date of this press release. Subsequent events and developments may cause those views to change. However, while LakeShore Biopharma may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of LakeShore Biopharma as of any date subsequent to the date of this press release. Except as may be required by law, LakeShore Biopharma does not undertake any duty to update these forward-looking statements.
听
听
LAKESHORE BIOPHARMA CO., LTD AND SUBSIDIARIES | ||||||||||||
CONSOLIDATED BALANCE SHEET (AUDITED) | ||||||||||||
As of March 31, | ||||||||||||
2024 | 2025 | 2025 | ||||||||||
(RMB) | (RMB) | (US$) | ||||||||||
ASSETS | ||||||||||||
Current assets | ||||||||||||
听 听 听 听Cash | 246,351,231 | 28,083,556 | $ | 3,912,340 | ||||||||
听 听 听 听Restricted cash | 200,000 | 79,401,410 | 11,061,465 | |||||||||
听 听 听 听 Accounts receivable | 444,161,291 | 500,916,815 | 69,783,067 | |||||||||
听 听 听 听 Advance to suppliers | 1,662,739 | 1,687,964 | 235,151 | |||||||||
听 听 听 听 Inventories | 203,422,602 | 227,591,892 | 31,705,984 | |||||||||
听 听 听 听 Prepaid expenses and other current assets | 7,370,089 | 4,536,363 | 631,964 | |||||||||
听 听Total current assets | 903,167,952 | 842,218,000 | 117,329,971 | |||||||||
Non-current assets | ||||||||||||
听 听 听 听Property, plant and equipment | 473,348,006 | 413,501,445 | 57,605,172 | |||||||||
听 听 听 听Operating lease right-of-use assets | 7,275,367 | 847,331 | 118,042 | |||||||||
听 听 听 听Deferred tax assets | 23,634,189 | 27,946,500 | 3,893,247 | |||||||||
听 听 听 听Intangible assets | 71,245,336 | 72,854,656 | 10,149,432 | |||||||||
听 听 听 听Other non-current assets | 34,356,506 | 10,295,279 | 1,434,242 | |||||||||
听 听 听 听Total non-current assets | 609,859,404 | 525,445,211 | 73,200,135 | |||||||||
听 听 听 听Total assets | 1,513,027,356 | 1,367,663,211 | $ | 190,530,106 | ||||||||
LIABILITIES AND SHAREHOLDERS' | ||||||||||||
Current liabilities | ||||||||||||
听 听 听 听Bank loans and other borrowings | 318,540,732 | 390,440,095 | $ | 54,392,479 | ||||||||
听 听 听 听Accounts payable | 67,774,798 | 49,551,779 | 6,903,093 | |||||||||
听 听 听 听Accrued expenses and other liabilities | 408,737,969 | 382,847,958 | 53,334,812 | |||||||||
听 听 听 听Operating lease liabilities | 5,156,540 | 457,012 | 63,667 | |||||||||
听 听 听 听Deferred government grants | 2,015,693 | 1,455,678 | 202,792 | |||||||||
听 听 听 听Total current liabilities | 802,225,732 | 824,752,522 | 114,896,843 | |||||||||
Non-current liabilities | ||||||||||||
听 听 听 听Bank loans and other borrowings | 98,983,780 | 23,503,471 | 3,274,285 | |||||||||
听 听 听 听Operating lease liabilities | 1,783,593 | - | - | |||||||||
听 听 听 听Deferred government grants | 20,279,945 | 16,207,745 | 2,257,912 | |||||||||
听 听 听 听Warrants liability | 4,548,004 | 3,444,842 | 479,903 | |||||||||
听 听 听 听Total non-current liabilities | 125,595,322 | 43,156,058 | 6,012,100 | |||||||||
听 听 听 听Total liabilities | 927,821,054 | 867,908,580 | 120,908,943 | |||||||||
Shareholders'(deficit)/equity | ||||||||||||
听 听 听 听Ordinary shares, par value | 26,105 | 28,603 | 3,985 | |||||||||
听 听 听 听Additional paid-in capital | 2,950,862,914 | 2,964,482,986 | 412,984,172 | |||||||||
听 听 听 听Accumulated deficit | (2,307,502,836) | (2,407,485,287) | (335,388,438) | |||||||||
听 听 听 听Accumulated other comprehensive loss | (58,179,881) | (57,271,671) | (7,978,556) | |||||||||
听 听 听 听Total shareholders' equity | 585,206,302 | 499,754,631 | 69,621,163 | |||||||||
听 听 听 听Total liabilities and shareholders' equity | 1,513,027,356 | 1,367,663,211 | $ | 190,530,106 | ||||||||
听
* | Gives retroactive effect to the Share Consolidation in October 2024. |
听
听
听
LAKESHORE BIOPHARMA CO., LTD AND SUBSIDIARIES | ||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (AUDITED) | ||||||||||||||||
Years Ended March 31, | ||||||||||||||||
2023 | 2024 | 2025 | 2025 | |||||||||||||
(RMB) | (RMB) | (RMB) | (US$) | |||||||||||||
Revenues | 687,201,070 | 573,418,256 | 614,961,584 | $ | 85,670,723 | |||||||||||
Cost of revenues | 153,360,262 | 117,688,301 | 107,772,147 | 15,013,812 | ||||||||||||
Gross profit | 533,840,808 | 455,729,955 | 507,189,437 | 70,656,911 | ||||||||||||
Operating expenses: | ||||||||||||||||
听 听 听 听Selling and marketing | 272,927,356 | 301,259,528 | 281,429,426 | 39,206,128 | ||||||||||||
听 听 听 听General and administrative | 72,939,790 | 140,086,062 | 128,967,761 | 17,966,588 | ||||||||||||
听 听 听 听Impairment loss on inventory, property, plant and | 8,655,487 | 157,415,875 | 36,715,041 | 5,114,798 | ||||||||||||
听 听 听 听Research and development | 318,700,526 | 302,800,992 | 146,369,093 | 20,390,779 | ||||||||||||
Total operating expenses | 673,223,159 | 901,562,457 | 593,481,321 | 82,678,293 | ||||||||||||
Loss from operations | (139,382,351) | (445,832,502) | (86,291,884) | (12,021,382) | ||||||||||||
Other income (expenses): | ||||||||||||||||
听 听 听 听Late fees for taxes other than income tax | (3,603) | - | - | - | ||||||||||||
听 听 听 听Late fees for social security insurance | (747,609) | (756,201) | (454,863) | (63,367) | ||||||||||||
听 听 听 听Government grants | 26,072,517 | 20,708,778 | 5,125,566 | 714,046 | ||||||||||||
听 听 听 听Financial expenses | (30,857,673) | (44,344,808) | (15,739,410) | (2,192,668) | ||||||||||||
听 听 听 听Fair value changes of warrant liability | 21,358 | 4,458,844 | 1,149,792 | 160,178 | ||||||||||||
听 听 听 听Other income(expense) | 551,760 | 10,572,411 | (4,718,525) | (657,341) | ||||||||||||
听 听 听 听Total other income (expense) | (4,963,250) | (9,360,976) | (14,637,440) | (2,039,152) | ||||||||||||
Loss before income taxes | (144,345,601) | (455,193,478) | (100,929,324) | (14,060,534) | ||||||||||||
Income tax benefit(expense) | (1,133,504) | 21,728,607 | 946,873 | 131,910 | ||||||||||||
Net loss | (145,479,105) | (433,464,871) | (99,982,451) | (13,928,624) | ||||||||||||
听 听 听 听Accretion to redemption value of convertible | (137,991,697) | - | - | - | ||||||||||||
Net loss attributable to LakeShore Group | (283,470,802) | (433,464,871) | (99,982,451) | $ | (13,928,624) | |||||||||||
Net loss | (145,479,105) | (433,464,871) | (99,982,451) | $ | (13,928,624) | |||||||||||
听 听 听 听Other comprehensive income (loss), net of tax: | (137,500,063) | (3,767,798) | 908,210 | 126,523 | ||||||||||||
Total comprehensive loss | (282,979,168) | (437,232,669) | (99,074,241) | $ | (13,802,101) | |||||||||||
Loss per share*: | ||||||||||||||||
鈥� Basic and Diluted | (23.55) | (40.54) | (5.22) | $ | (0.73) | |||||||||||
Weighted average number of ordinary shares | ||||||||||||||||
鈥� Basic and Diluted | 6,178,547 | 10,692,312 | 19,158,907 | 19,158,907 | ||||||||||||
听
* | Gives retroactive effect to the Share Consolidation in October 2024. |
听
Lakeshore Biopharma Co., Ltd | ||||||
Unaudited Reconciliations of GAAP And Non-GAAP Results | ||||||
Years Ended March 31, | ||||||
2024 | 2025 | 2025 | ||||
RMB | RMB | US$ | ||||
Net income (loss) | (433,464,871) | (99,982,451) | $ | (13,928,624) | ||
Add: income tax benefit (expense) | (21,728,607) | (946,873) | (131,910) | |||
Add: financial expenses | 44,344,808 | 15,739,410 | 2,192,668 | |||
Add: depreciation and amortization | 42,185,383 | 36,651,608 | 5,105,961 | |||
EBITDA | (368,663,287) | (48,538,306) | (6,761,905) | |||
Add: share-based compensation expenses | 9,789,686 | 13,557,214 | 1,888,665 | |||
Add: impairment loss on inventory, property, | 157,415,875 | 36,715,041 | 5,114,798 | |||
late fees related to social security insurance | 756,201 | 454,863 | 63,367 | |||
Add: other income (expense) | (10,572,411) | 4,718,525 | 657,341 | |||
Add: fair value changes of warrant liability | (4,458,844) | (1,149,792) | (160,178) | |||
Add: government grants | (20,708,778) | (5,125,566) | (714,046) | |||
Adjusted EBITDA | (236,441,558) | 631,979 | $ | 88,041 | ||
Years Ended March 31, | ||||||
2024 | 2025 | 2025 | ||||
RMB | RMB | US$ | ||||
Net income (loss) | (433,464,871) | (99,982,451) | $ | (13,928,624) | ||
Add: share-based compensation expenses | 9,789,686 | 13,557,214 | 1,888,665 | |||
Add: impairment loss on inventory, property, | 157,415,875 | 36,715,041 | 5,114,798 | |||
Add: loss on disposal of property, plant and | 13,135 | 9,777,030 | 1,362,045 | |||
Adjusted net income (loss) | (266,259,310) | (39,933,166) | $ | (5,563,117) | ||
听
听
听
View original content:
SOURCE LakeShore Biopharma Co., Ltd.
FAQ
What were LakeShore Biopharma's (LSB) key financial results for FY2025?
How many doses of YSJATM rabies vaccine has LakeShore Biopharma distributed in China?
What is LSB's revenue guidance for Fiscal Year 2026?
When does LakeShore Biopharma expect to receive market approval for its simplified four-dose YSJATM regimen?
What are the main challenges facing LakeShore Biopharma in 2025?
